Novartis recently shared promising findings from the Phase III APPLAUSE-IgAN study of Fabhalta® (iptacopan), a Factor B inhibitor targeting the alternative complement pathway, in patients with IgA nephropathy (IgAN). In this interim analysis, patients treated with Fabhalta experienced a significant…
Agenus Inc. (NASDAQ: AGEN), a renowned player in the realm of discovering and advancing novel immunological treatments for diverse cancers, has disclosed the latest outcomes from its Phase 1 clinical assessment of BOT/BAL combination therapy targeting patients with metastatic CRC…
Novartis has officially released the offer document for its subsidiary, Novartis BidCo AG’s, voluntary public takeover bid for all outstanding shares of MorphoSys AG, inclusive of MorphoSys American Depositary Shares (ADS), at an offer price of EUR 68.00 per share…
Pfizer Inc. (NYSE: PFE) has reported promising top-line data on the immunogenicity and safety of ABRYSVO® from its pivotal Phase 3 clinical trial MONeT (RSV IMmunizatiON Study for AdulTs at Higher Risk of Severe Illness). The trial, registered under NCT05842967,…
Allergan Aesthetics, a subsidiary of AbbVie Inc. (NYSE: ABBV), has unveiled two new additions to the SkinMedica® lineup, developed by the creators of BOTOX® Cosmetic. These groundbreaking products, the SkinMedica® Acne Clarifying Treatment and SkinMedica® Pore Purifying Gel Cleanser, mark…
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has unveiled comprehensive findings from the Phase 3 Balance study of olezarsen, its leading independent investigational medication, targeted at adults grappling with familial chylomicronemia syndrome (FCS). The study revealed that the monthly administration of olezarsen…
A joint mission led by the World Health Organization (WHO) and several other agencies visited Al-Shifa Hospital in north Gaza on April 5 to assess the damage caused by the ongoing conflict and identify necessary steps for its restoration. The…
AstraZeneca’s Imfinzi Shows Significant Improvement in Survival Rates for Limited-Stage Small Cell Lung Cancer Patients A recent Phase III trial, ADRIATIC, revealed promising outcomes for AstraZeneca’s Imfinzi (durvalumab) in treating patients with limited-stage small cell lung cancer (LS-SCLC). The trial…
Bristol Myers Squibb (NYSE: BMY) has unveiled its 2023 Environmental, Social, and Governance (ESG) Report, spotlighting significant progress, a refined strategy, and ambitious goals in its ESG initiatives. Rooted in its mission to pioneer innovative medicines aiding patients in overcoming…
AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been officially accepted in the United States. This application targets the treatment of adult patients grappling with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC…
The CVS Health® (NYSE: CVS) today announced more than $3 million in new grants to support organizations in Phoenix working to increase equitable access to health care, address social determinants of health and educate the community on the effects of air…
Bristol Myers Squibb (NYSE: BMY) has introduced a $1.8 million initiative aimed at promoting health equity by tackling social determinants of health (SDoH) in four countries with underserved patient populations: Brazil, India, Thailand, and the United Kingdom. These new grants…